{"title":"4周维持ICS-福莫特罗对新诊断轻度哮喘的成人:对症状、肺功能和炎症的影响","authors":"Yan Zhou, Xue Zhang, Zichong Xu, Jinwen Wang, Yilin Pan, Yingying Zhang, Xue Tian, Yuning Huang, Chengjian Lv, Qi Zheng, Wuping Bao, Min Zhang","doi":"10.1007/s11882-025-01217-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This study aimed to determine whether patients with newly diagnosed mild asthma benefit more from initiating treatment with maintenance inhaled corticosteroids (ICS) plus formoterol versus ICS alone. We compared the effects of these two 4-week maintenance strategies on asthma control, lung function, and airway inflammation.</p><p><strong>Recent findings: </strong>Recent evidence supports the effectiveness of as-needed ICS-formoterol in mild asthma management. However, data on initial short-term maintenance strategies remain limited. Most studies focus on long-term outcomes or symptom-driven therapy, with little insight into the early phase and its impact on inflammation and lung function. Notably, GINA 2024 emphasizes that \"mild asthma\" is a retrospective label and may not reliably guide the selection of the appropriate initial treatment step. Even in so-called mild asthma, severe outcomes may occur, highlighting the need for early, objective assessment to guide treatment decisions. In this retrospective analysis of two prospective studies including 128 patients with newly diagnosed mild asthma, both the ICS-formoterol and ICS groups showed improvements in asthma control, lung function, and airway inflammation. However, the ICS-formoterol group achieved significantly greater improvements in Asthma Control Test scores, Asthma Control Questionnaire scores, large airway function (FEV<sub>1</sub>, FEV<sub>1</sub>/FVC), small airway function, and eosinophil reduction, particularly in patients with baseline small airway dysfunction. FEV<sub>1</sub> reversibility in baseline bronchodilation test was positively correlated with improvements in FEV<sub>1</sub>, FEV<sub>1</sub>/FVC, and eosinophil count reduction in the ICS-formoterol group. These findings support 4-week ICS-formoterol maintenance therapy as an effective initial strategy in mild asthma, with reassessment guiding longer-term management.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"40"},"PeriodicalIF":4.6000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"4-Week Maintenance ICS-Formoterol versus ICS in Adults Newly Diagnosed Mild Asthma: Effects on Symptoms, Lung Function, and Inflammation.\",\"authors\":\"Yan Zhou, Xue Zhang, Zichong Xu, Jinwen Wang, Yilin Pan, Yingying Zhang, Xue Tian, Yuning Huang, Chengjian Lv, Qi Zheng, Wuping Bao, Min Zhang\",\"doi\":\"10.1007/s11882-025-01217-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>This study aimed to determine whether patients with newly diagnosed mild asthma benefit more from initiating treatment with maintenance inhaled corticosteroids (ICS) plus formoterol versus ICS alone. We compared the effects of these two 4-week maintenance strategies on asthma control, lung function, and airway inflammation.</p><p><strong>Recent findings: </strong>Recent evidence supports the effectiveness of as-needed ICS-formoterol in mild asthma management. However, data on initial short-term maintenance strategies remain limited. Most studies focus on long-term outcomes or symptom-driven therapy, with little insight into the early phase and its impact on inflammation and lung function. Notably, GINA 2024 emphasizes that \\\"mild asthma\\\" is a retrospective label and may not reliably guide the selection of the appropriate initial treatment step. Even in so-called mild asthma, severe outcomes may occur, highlighting the need for early, objective assessment to guide treatment decisions. In this retrospective analysis of two prospective studies including 128 patients with newly diagnosed mild asthma, both the ICS-formoterol and ICS groups showed improvements in asthma control, lung function, and airway inflammation. However, the ICS-formoterol group achieved significantly greater improvements in Asthma Control Test scores, Asthma Control Questionnaire scores, large airway function (FEV<sub>1</sub>, FEV<sub>1</sub>/FVC), small airway function, and eosinophil reduction, particularly in patients with baseline small airway dysfunction. FEV<sub>1</sub> reversibility in baseline bronchodilation test was positively correlated with improvements in FEV<sub>1</sub>, FEV<sub>1</sub>/FVC, and eosinophil count reduction in the ICS-formoterol group. These findings support 4-week ICS-formoterol maintenance therapy as an effective initial strategy in mild asthma, with reassessment guiding longer-term management.</p>\",\"PeriodicalId\":55198,\"journal\":{\"name\":\"Current Allergy and Asthma Reports\",\"volume\":\"25 1\",\"pages\":\"40\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Allergy and Asthma Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11882-025-01217-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Allergy and Asthma Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11882-025-01217-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
4-Week Maintenance ICS-Formoterol versus ICS in Adults Newly Diagnosed Mild Asthma: Effects on Symptoms, Lung Function, and Inflammation.
Purpose of review: This study aimed to determine whether patients with newly diagnosed mild asthma benefit more from initiating treatment with maintenance inhaled corticosteroids (ICS) plus formoterol versus ICS alone. We compared the effects of these two 4-week maintenance strategies on asthma control, lung function, and airway inflammation.
Recent findings: Recent evidence supports the effectiveness of as-needed ICS-formoterol in mild asthma management. However, data on initial short-term maintenance strategies remain limited. Most studies focus on long-term outcomes or symptom-driven therapy, with little insight into the early phase and its impact on inflammation and lung function. Notably, GINA 2024 emphasizes that "mild asthma" is a retrospective label and may not reliably guide the selection of the appropriate initial treatment step. Even in so-called mild asthma, severe outcomes may occur, highlighting the need for early, objective assessment to guide treatment decisions. In this retrospective analysis of two prospective studies including 128 patients with newly diagnosed mild asthma, both the ICS-formoterol and ICS groups showed improvements in asthma control, lung function, and airway inflammation. However, the ICS-formoterol group achieved significantly greater improvements in Asthma Control Test scores, Asthma Control Questionnaire scores, large airway function (FEV1, FEV1/FVC), small airway function, and eosinophil reduction, particularly in patients with baseline small airway dysfunction. FEV1 reversibility in baseline bronchodilation test was positively correlated with improvements in FEV1, FEV1/FVC, and eosinophil count reduction in the ICS-formoterol group. These findings support 4-week ICS-formoterol maintenance therapy as an effective initial strategy in mild asthma, with reassessment guiding longer-term management.
期刊介绍:
The aim of Current Allergy and Asthma Reports is to systematically provide the views of highly selected experts on current advances in the fields of allergy and asthma and highlight the most important papers recently published. All reviews are intended to facilitate the understanding of new advances in science for better diagnosis, treatment, and prevention of allergy and asthma.
We accomplish this aim by appointing international experts in major subject areas across the discipline to review select topics emphasizing recent developments and highlighting important new papers and emerging concepts. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Over a one- to two-year period, readers are updated on all the major advances in allergy and asthma.